In light of the emerging evidence that young women with luminal-B tumors have particularly disparate outcomes, and in consideration of the high deregulation of the PI3K pathway in tumors arising in young patients [9],[20] and its vital role in endocrine resistance [61], targeting the PI3K pathway is an approach that is worth investigating further in young breast cancer patients. The gene discussed is PIK3CA; the disease is breast cancer.